ARDELYX, INC. (ARDX) FY2025 10-K Annual Report
ARDELYX, INC. (ARDX) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
ARDELYX, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: Development and commercialization of innovative medicines focused on tenapanor-based therapies for gastrointestinal and kidney diseases
- • New emphasis on Phase 3 trial initiation in January 2026 for tenapanor in chronic idiopathic constipation (CIC), targeting a new patient population of 34 million Americans
- • Strategic shift: Navigating the 2025 Medicare Part D reimbursement change eliminating coverage for XPHOZAH, focusing on preserving patient access despite revenue impact
- • Notable quantitative metric: Cash, cash equivalents, and short-term investments increased 5.8% to $264.7 million as of December 31, 2025, supporting ongoing operations and growth
- • Significant IP advancement: Receipt of U.S. Patent No. 12,539,299 in January 2026 extending protection for tenapanor formulations in IBSRELA and XPHOZAH until 2042
Management Discussion & Analysis
- • Total revenue $407.3M, up 22% YoY from $333.6M in 2024; product sales $377.8M, up 18% YoY from $319.2M
- • Operating expenses $448.3M, up 24% YoY from $361.6M; cost of sales down 22% to $39.5M vs $50.6M; R&D up 37% to $71.5M; SG&A up 30% to $337.2M
- • Best performing segment: IBSRELA sales $274.2M, up 73% YoY; worst: XPHOZAH sales $103.6M, down 36% YoY due to Medicare Part D reimbursement loss
- • Cash, cash equivalents, and short-term investments $264.7M vs. $250.1M in 2024; no shares sold under ATM offerings in 2025; debt financing amended with $50M drawn in June 2025 plus $100M available through 2026
- • Management outlook: ongoing Phase 3 trial for CIC indication with topline data in H2 2027; advancing next-generation NHE3 inhibitor program; key risk in payor mix and reimbursement changes impacting sales and GTN adjustments (30.2% in 2025 vs 25.6% prior year)
Risk Factors
- • Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue
- • Geopolitical/macro risk: Foreign price controls in Europe, Canada, Japan, China may limit IBSRELA and XPHOZAH pricing and reduce international revenue
- • Operational risk: Dependence on third-party CMOs for manufacturing IBSRELA and XPHOZAH with single-source suppliers risks supply interruptions and regulatory non-compliance
- • Competitive risk: Market acceptance and payer coverage pressures for IBSRELA and XPHOZAH amid existing and developing alternative therapies
- • Financial risk: Accumulated deficit of $946.9M as of Dec 31, 2025, with continued losses risking cash flow sustainability and reliance on future fundraising
ARDELYX, INC. FY2025 Key Financial MetricsXBRL
Revenue
$407M
▲ +22.1% YoY
Net Income
-$62M
▼ -57.4% YoY
Operating Margin
-10.1%
▼ -168bp YoY
Net Margin
-15.1%
▼ -339bp YoY
ROE
-36.9%
▼ -1431bp YoY
Total Assets
$502M
▲ +15.1% YoY
EPS (Diluted)
$-0.26
▼ -52.9% YoY
Operating Cash Flow
-$42M
▲ +5.2% YoY
Source: XBRL data from ARDELYX, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on ARDELYX, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.